Trial Profile

Confirmatory Phase 1 Trial of SYNC-T - Immunotherapy Regimen Given After Controlled Cellular Lysis for Patients With Advanced/Metastatic Castration-Resistant Prostate Cancer (mCRPC) or Those With Metastatic Prostate Cancer Who Refused Hormone Therapy and Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jun 2025 According to a Syncromune media release, the updated clinical data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
02 Jun 2025 Results presented in the Syncromune Media Release
23 May 2025 According to a Syncromune media release, company announced the publication of an abstract that will be presented orally at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com